NTLA Initiates Rolling Submission of BLA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
遗传性血管水肿。
发布于 上海
Research_医药人-Daniel 26-04-28 08:41
NTLA Initiates Rolling Submission of BLA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
遗传性血管水肿。